AACE/ACE disease state clinical review: Dopamine agonists for hyperprolactinemia and the risk of cardiac valve disease

Endocrine Practice

Volumn 20, Issue 6, 2014, Pages 608-616

  Samson, Susan L ^a   Ezzat, Shereen ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT DERIVATIVE; ERGOTAMINE; LISURIDE; METHYSERGIDE; PERGOLIDE; PRAMIPEXOLE; QUINAGOLIDE; ROPINIROLE; TERGURIDE; ERGOLINE DERIVATIVE;

ARTICLE; CANCER SURGERY; CASE CONTROL STUDY; CLINICAL PRACTICE; DISEASE REGISTRY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; HEALTH CARE COST; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; MEDLINE; PARKINSON DISEASE; PROLACTINOMA; PROSPECTIVE STUDY; RECURRENCE RISK; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION; VALVULAR HEART DISEASE; CHEMICALLY INDUCED; RISK;

DOPAMINE AGONISTS; ERGOLINES; HEART VALVE DISEASES; HUMANS; HYPERPROLACTINEMIA; RISK;

EID: 84903576700     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP14148.RA     Document Type: Article

References (69)

1. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: A systematic review. Cancer. 2004.;101: 613Y619
2. Serri O, Rasio E, Beauregard H, Hardy J, Somma M. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med. 1983.;309:280Y283
3. Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: Early results and long-term outcome. J Clin Endocrinol Metab. 2002.;87:3180Y3186
4. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011.; 96:273Y288
5. Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) .;65:265Y273
6. Besser GM, Parke L, Edwards CR, Forsyth IA, McNeilly AS. Galactorrhoea: Successful treatment with reduction of plasma prolactin levels by brom-ergocryptine. Br Med J. 1972.;3:669Y672
7. Nillius SJ, Bergh T, Lundberg PO, Stahle J, Wide L. Regression of a prolactin-secreting pituitary tumor during long-term treatment with bromocriptine. Fertil Steril. 1978.;30:710Y712
8. Reichlin S. The prolactinoma problem. N Engl J Med. 1979.;300:313Y315
9. Klibanski A. Clinical practice. Prolactinomas. N Engl J Med. 2010.;362:1219Y1226
10. Ferrari C, Barbieri C, Caldara R, et al. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab. 1986.;63:941Y945
11. Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: A meta-analysis. J Clin Endocrinol Metab. 2011.;96:1327Y1335
12. Katznelson L, Atkinson JL, Cook DM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. Endocr Pract. 2011.;17 Suppl 4:1Y44
13. Pivonello R, Ferone D, de Herder WW, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab. 2004.;89:2452Y2462
14. Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing's disease: Effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009.;94:223Y230
15. Pivonello R, Matrone C, Filippella M, et al. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: Comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab. 2004.;89: 1674Y1683
16. Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J. Drug-induced fibrotic valvular heart disease. Lancet. 2009.;374:577Y585
17. Hutcheson JD, Setola V, Roth BL, Merryman WD. Serotonin receptors and heart valve disease-it was meant 2B. Pharmacol Ther. 2011.;132:146Y157
18. Hutcheson JD, Ryzhova LM, Setola V, Merryman WD. 5-HT(2B) antagonism arrests non-canonical TGF-β1- induced valvular myofibroblast differentiation. J Mol Cell Cardiol. 2012.;53:707Y714
19. Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999.;83: 897Y902
20. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: A population-based study. Lancet. 2006.; 368:1005Y1011
21. Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med. 1998.;339:725Y732
22. Newman-Tancredi A, Cussac D, Quentric Y, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther. 2002.;303:815Y822
23. Kvernmo T, Härtter S, Burger E. A review of the receptor- binding and pharmacokinetic properties of dopamine agonists. Clin Ther. 2006.;28:1065Y1078
24. Jähnichen S, Horowski R, Pertz HH. Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol. 2005.;513:225Y228
25. Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology. 2003.;61:859Y861
26. Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Jr. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology. 2004.;63:301Y304
27. Junghanns S, Fuhrmann JT, Simonis G, et al. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: A reader-blinded monocenter echocardiography study. Mov Disord. 2007.;22:234Y238
28. Peralta C, Wolf E, Alber H, et al. Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study. Mov Disord. 2006.;21:1109Y1113
29. Pinero A, Marcos-Alberca P, Fortes J. Cabergolinerelated severe restrictive mitral regurgitation. N Engl J Med. 2005.;353:1976Y1977
30. Kenangil G, Ozekmekçi S, Koldas L, Sahin T, Erginöz E. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline. Clin Neurol Neurosurg. 2007.;109:350Y353
31. Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists. Mov Disord. 2004.;19: 656Y662
32. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: A casecontrol study. Neurology. 2006.;67:1225Y1229
33. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007.;356:29Y38
34. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007.;356: 39Y46
35. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Cardiovasc Ther. 2011.; 29:404Y410
36. Steiger M, Jost W, Grandas F, Van CG. Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: A systematic review. J Neural Transm. 2009.;116:179Y191
37. Serratrice J, Disdier P, Habib G, Viallet F, Weiller PJ. Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev. 2002.;10:334Y336
38. Tan LC, Ng KK, Au WL, Lee RK, Chan YH, Tan NC. Bromocriptine use and the risk of valvular heart disease. Mov Disord. 2009.;24:344Y349
39. Debove P, Simon F, Vaylet F, Renard JL, L'Her P. Pleuropneumopathy caused by bromocriptine in a patient with Parkinson disease. Review of the literature apropos of a new case [article in French]. Ann Med Interne (Paris);149:167Y171
40. Ciubotaru V, Poinsignon Y, Brunet-Bourgin F, Mestassi M, Rosenbaum D. Severe pleuropericarditis induced by long-term bromocriptin therapy, report of a case and review of the literature [article in French]. Rev Med Interne. 2004.;25:310Y314
41. Demonet JF, Rostin M, Dueymes JM, Ioualalen A, Montastruc JL, Rascol A. Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine. Clin Neuropharmacol. 1986.;9:200Y201
42. Melmed S, Braunstein GD. Bromocriptine and pleuropulmonary disease. Arch Intern Med. 1989.;149:258Y259
43. Kains JP, Hardy JC, Chevalier C, Collier A. Retroperitoneal fibrosis in two patients with Parkinson's disease treated with bromocriptine. Acta Clin Belg. 1990.; 45:306Y310
44. Vallette S, Serri K, Rivera J, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary. 2009.;12:153Y157
45. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol. 2008.;159:R11-R14
46. Auriemma RS, Pivonello R, Perone Y, et al. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol. 2013.;169:359Y366
47. Delgado V, Biermasz NR, van Thiel SW, et al. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. Clin Endocrinol (Oxf). 2012.;77:99Y105
48. Halperin I, Aller J, Varela C, et al. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma. Clin Endocrinol (Oxf). 2012.;77:275Y280
49. Elenkova A, Shabani R, Kalinov K, Zacharieva S. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur J Endocrinol. 2012.; 167:17Y25
50. Boguszewski CL, dos Santos CM, Sakamoto KS, Marini LC, de Souza AM, Azevedo M. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. Pituitary. 2012.;15:44Y49
51. Tan T, Cabrita IZ, Hensman D, et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol (Oxf) .;73:369Y374
52. Lafeber M, Stades AM, Valk GD, Cramer MJ, Teding van BF, Zelissen PM. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur J Endocrinol. 2010.;162:667Y675
53. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) ;70:104Y108
54. Devin JK, Lakhani VT, Byrd BF III, Blevins LS Jr. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr Pract. 2008.;14:672Y677
55. Kars M, Delgado V, Holman ER, et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab. 2008.;93:3348Y3356
56. Bogazzi F, Buralli S, Manetti L, et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract. 2008.;62:1864Y1869
57. Lancellotti P, Livadariu E, Markov M, et al. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol. 2008.;159:1Y5
58. Colao A, Galderisi M, Di Sarno A, et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab. 2008.;93:3777Y3784
59. De Vecchis R, Esposito C, Ariano C. Cabergoline use and risk of fibrosis and insufficiency of cardiac valves: Metaanalysis of observational studies. Herz. 2013.;38:868Y880
60. Steffensen C, Maegbaek ML, Laurberg P, et al. Heart valve disease among patients with hyperprolactinemia: A nationwide population-based cohort study. J Clin Endocrinol Metab. 2012.;97:1629Y1634
61. Colao A, Spinelli L, Marzullo P, et al. High prevalence of cardiac valve disease in acromegaly: An observational, analytical, case-control study. J Clin Endocrinol Metab. 2003.; 88:3196Y3201
62. Maione L, Garcia C, Bouchachi A, et al. No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. J Clin Endocrinol Metab. 2012.;97:E1714-E1719
63. Babey M, Sahli R, Vajtai I, Andres RH, Seiler RW. Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists. Pituitary. 2011.;14: 222Y230
64. Lee EJ, Ahn JY, Noh T, Kim SH, Kim TS, Kim SH. Tumor tissue identification in the pseudocapsule of pituitary adenoma: Should the pseudocapsule be removed for total resection of pituitary adenoma? Neurosurgery. 2009.; 64:62Y69
65. Dekkers OM, Lagro J, Burman P, Jorgensen JO, Romijn JA, Pereira AM. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: Systematic review and meta-analysis. J Clin Endocrinol Metab. 2010.;95:43Y51
66. Kwancharoen R, Auriemma RS, Yenokyan G, Wand GS, Colao A, Salvatori R. Second attempt to withdraw cabergoline in prolactinomas: A pilot study. Pituitary. 2013.; Epub ahead of print.
67. Schultz PN, Ginsberg L, McCutcheon IE, Samaan N, Leavens M, Gagel RF. Quinagolide in the management of prolactinoma. Pituitary. 2000.;3:239Y249
68. Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf. 1996.;14:228Y238
69. Barlier A, Jaquet P. Quinagolide-a valuable treatment option for hyperprolactinaemia. Eur J Endocrinol. 2006.; 154:187Y195.